Geninus지니너스
389030 · KOSDAQ · ₩389030 · 지니너스
- Market cap
- ₩53B
- Enterprise value
- ₩22B
- P/E
- —
- P/B
- 1.3×
- Dividend yield
- 0.0%
- ROE
- −50.0%
- Net margin
- −180.5%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−79.4% from the high
₩1,322Today: ₩1,322 – ₩1,436₩6,480
Returns
- 1W−15.5%
- 1M−31.2%
- 3M−31.7%
- 6M−74.2%
- YTD−61.9%
- 1Y−37.3%
- Volume today
- 456,327
- 1.0× the 20-day average
- Traded today
- ₩630M
- Listed shares
- 39,392,271
- EPS (12 months)
- −₩517
- Earnings yield −38.7%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 42 of 100 (50 is a normal day for this stock).
- SentimentMixedNews: Routine filings with no clear positive or negative news. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-31.4% over the last month; the price is below its 20-day average.
- News impactLow2 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Geninus stock overview
Geninus (지니너스, KRX: 389030) is listed on KOSDAQ, in the Biotech & Pharma sector. , Ltd. Its shares closed at ₩1,335 on Oct 27, 2026, down 4.16% on the day, giving it a market value of ₩53B.
Key facts
- Market cap
- ₩53B
- Sector
- Biotech & Pharma
- Latest price change
- −4.16%
- As of
- Oct 27, 2026
- Main business
- , Ltd.
Quick answers about Geninus
- What does Geninus do?
- , Ltd. is a Korean bio venture spun off from the Samsung Genome Institute at Samsung Medical Center in 2018, focused on genome analysis technology R&D and the development and manufacture of genome analysis solutions. It runs three business lines: a platform for pharmaceutical companies (IntelliMed, MEDINSIGHT and SPACEINSIGHT for drug target discovery and clinical strategy), analysis solutions for researchers in single-cell and spatial omics, and diagnostic products including the CancerSCAN NGS cancer test, the LiquidSCAN liquid biopsy test, and the HealthSCAN genetic risk test.
- What is the market cap of Geninus?
- The market capitalisation of Geninus was ₩53B at the close on Oct 27, 2026.
- Who are the largest shareholders of Geninus?
- According to the latest official filings, the largest reported holders are Park Ung-yang (26.71%, as of May 29, 2026); Korea Investment Partners (9.85%, as of May 28, 2025); KB Investment (7.38%, as of May 29, 2026).
- When is the next earnings report from Geninus?
- Korean companies rarely announce results dates in advance. Based on when Geninus filed the same report in past years, its next 3q results is expected between Nov 14, 2026 and Nov 24, 2026.
Company profile
Geninus Co., Ltd. is a Korean bio venture spun off from the Samsung Genome Institute at Samsung Medical Center in 2018, focused on genome analysis technology R&D and the development and manufacture of genome analysis solutions. It runs three business lines: a platform for pharmaceutical companies (IntelliMed, MEDINSIGHT and SPACEINSIGHT for drug target discovery and clinical strategy), analysis solutions for researchers in single-cell and spatial omics, and diagnostic products including the CancerSCAN NGS cancer test, the LiquidSCAN liquid biopsy test, and the HealthSCAN genetic risk test. Its customers include global and domestic large pharmaceutical companies, hospitals and research institutions, and its activities are based in Korea with partnerships with overseas pharmaceutical firms.
Written by AI from the company's latest annual report.
- Korean name
- 지니너스
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 박웅양
- Founded
- Apr 2018
- Listed
- Nov 2021
- Listed shares
- 39,392,271
- Fiscal year ends
- Month 12
- Website
- kr-geninus.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Insider shareholding reportOct 28, 2026
- Adjustment of Conversion PriceOct 26, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Amended: Insider shareholding reportAug 4, 2026
- [Amendment] Exercise of Conversion RightJun 9, 2026
Titles in Korean until English translations are added.
Also known as: Geninus / 지니너스 / 389030 / KRX:389030
Source: KRX statistical information